key: cord-0703801-9ximwada authors: Rochwerg, Bram; Agoritsas, Thomas; Diaz, Janet; Askie, Lisa title: WHO COVID-19 therapeutic guidelines date: 2021-07-08 journal: Lancet DOI: 10.1016/s0140-6736(21)01331-3 sha: 06953933b5e9bda410fd624f4af1dec95e97a81d doc_id: 703801 cord_uid: 9ximwada nan In response to Nicholas White and colleagues, 1 we offer these clarifications. WHO guideline development methods are prespecified, 2 abiding by principles for producing trustworthy guidelines. The WHO COVID-19 Therapeutics Guideline Development Group (GDG) is composed of external experts, with geographical representation and gender balance, including COVID-19 survivors, ethicists, and methodologists who are vetted for potential conflicts of interest. The GDG prioritises outcomes and identifies subgroups to be considered for each recommendation, always including age and disease severity (using WHO COVID-19 definitions of nonsevere, severe, and critical). 3 As WHO guidelines need to be globally applicable, the GDG deliberately used these disease severity classifications, based on clinical indicators, to assess subgroup effects rather than stage of disease (viral and inflammatory phases). The GDG avoided using access to health care (inpatient or outpatient) to define patient subgroups because who is admitted to hospital, when, and how can differ substantially across jurisdictions. The meta-analysis team did a network meta-regression based on the prespecified subgroup variables, focusing on within-trial rather than between-trial comparisons. The GDG assessed the credibility of results from the subgroup analyses using the Instrument to assess the Credibility of Effect Modification Analyses tool, 4 which uses structured questions to derive an overall credibility rating. Regarding hydroxychloroquine treatment for COVID-19: after assessing results, the GDG concluded there was no credible subgroup effect for disease severity and thus issued a strong recommendation against hydroxychloroquine that applied across severities. Finally, WHO has issued separate guidelines for therapeutics 2 and prophylactic drugs, 5 with separate analyses for these indications, upsurge are due to limited access to health facilities, poorly developed surveillance systems, insufficient testing capacity, restricted international arrivals limiting virus introduction, reduced internal mobility, and demographics. It is erroneous to think that the spread of COVID-19 can be solely explained by poor social determinants of health and misconduct of governments. According to the WHO COVID-19 dashboard, as of May 18, 2021, the ten countries reporting the highest number of cases included the USA, France, the UK, Italy, Germany, and Spain, all of which have democratic systems and some of the highest gross domestic product in the world. COVID-19 is a new and complex disease which is still misunderstood, and we are encouraging impartial, collaborative research from experts in virology, epidemiology, vaccinology, sociology, and economy. Social determinants of health are key factors in the pandemic, and we have clearly acknowledged this point, 2 but until high vaccination coverage has been reached, public health and social measures are the only effective measures to control the spread of SARS-CoV-2. Reasons for the decreasing adherence to public health and social measures include a decrease of trust in governments, a denial of the pandemic among populations, and fatigue due to imposed restrictions. Most of these reasons are not mentioned by Khuloud Alsaba. There is no evidence that any Eastern Mediterranean region government has denied the pandemic. On the contrary, at the request of governments in the region, WHO has done review missions that include assessment of all aspects of the response, including governance, whole-of-government, and wholeof-society approaches. 3 During the regular ministerial meetings convened by the WHO Eastern Mediterranean region, there has been no COVID-19 denial, although strategic priorities and approaches might vary. The WHO Health Emergency programme was established to respond to the health needs of vulnerable populations. 4 The Eastern Mediterranean region is home to 43% of people who need humanitarian assistance and the source of 64% of the world's refugees, 5 and where access to basic sanitation and drinking water is denied to 174 million and 84 million people, respectively. These people are at higher risk of infection by the SARS-CoV-2 virus. However, the lowest COVID-19 incidence and mortality rates are reported in the most fragile countries within the Eastern Mediterranean region (appendix), and no major upsurge of cases has been reported in refugee camps. The under-reporting of cases and deaths, and the absence of See Online for appendix Helmut Fohringer/Getty Images infections suggests a worrying lack of clinical judgement. 2 The recent separate guidelines on COVID-19 chemoprophylaxis, 3 which contain judgements on mortality prevention derived from trials with no mortality, have only magnified concerns about the WHO assessments. 4, 5 The world looks to WHO for guidance and leadership in these difficult times. Therapeutic guidelines should be based on an understanding of the disease process, the health needs and health-system capabilities, the clinical pharmacology of the drugs, and the quality and weight of evidence. When advising on potential treatments, evidence from randomised clinical trials with patients who have severe COVID-19 should not be extrapolated to prevention and early treatment. 6 Despite the undoubted equitability, impartiality, and rigour of the WHO COVID-19 therapeutic guideline process, there is something fundamentally wrong with it. We declare no competing interests. Guidelines should not pool evidence from uncomplicated and severe COVID-19 WHO. Therapeutics and COVID-19: living guideline COVID-19 clinical management: living guidance Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses WHO living guideline: drugs to prevent COVID-19 We thank Bram Rochwerg and colleagues for information on the WHO therapeutic guideline development process. Unfortunately, they do not address our main concern: the unjustified extrapolation of evidence from randomised controlled trials in severe COVID-19 to therapeutic guidelines for uncomplicated illness. 1 Pooling summary data from studies with different severity definitions, deciding on inappropriate primary outcomes, and extrapolating from results in hospitalised patients to ambulant individuals with mild In their Comment on the double burden of HIV and COVID-19 in US Black communities, Errol Fields and colleagues 1 focus only on vulnerabilities as an alleged attribute of subpopulations, instead of stressing the importance of communities' agencies, resources, and strengths. Despite the authors' reflective analysis of structural inequalities and the intersectional character of systems of oppression, the vulnerability accentalthough benevolent-is inevitably alienating the groups that they are intending to prioritise. For example, the implication that being at risk for HIV is an inherent part of being gay created an artificial boundary between gay men, other members of the LGBTQ community, and larger society. 2 More importantly, disproportionately affected communities are uniquely resilient when it comes to survivorship, fighting stigma, dealing with loss, and living with health risks. An intersectionality of resilience 3 framework allows an analysis of paths to community empowerment in the face of oppression and to develop survivorship-based community health interventions.So far, experiences of survivorship do not translate into research. There is a substantial gap in addressing resilience: HIV research rarely identifies resilience at the community level, concerning itself only with resilience at individual or interpersonal levels. 4 In the case of HIV/AIDS in US Black communities, tales of community resilience are generously shared in art. This immense resource and the knowledge base should be used by scientific and professional communities. Commitment to what could be called community literacy, on the side of scientific and professional communities, would thus help to restore a gravely missed learning opportunity.